Posts Tagged ‘GLP-1 agonists’

Headlines and health plans depict the demand for advanced obesity medicines in terms of mania or a stampede. “The Ozempic craze is booming in the United States,” says the University of Kentucky healthcare system. But is it reasonable to describe the people seeking these medicines as crazed? Or is this really an expression of false […]

New observational research in Addiction suggests that the rates of drug and alcohol use might be lower by as much as half when people are taking GLP-1s. Specifically, half as many people with alcohol use disorder had episodes of intoxication if they were taking a GLP-1. Among people with opioid use disorder, the rate of […]

Amid a great deal of excitement about the value of GLP-1 medicines like semaglutide and tirzepatide for obesity, there is also a buzz of concern about muscle loss. Is it a reason to think twice about these new treatments? Or is it merely a reason for caution? Not Unique to GLP-1s Carla Prado, Stuart Phillips, […]

Caution is wise when observational studies compete for our attention. But this one, from JAMA Network Open, is intriguing. In a recent analysis of 33,006 persons with both type 2 diabetes and opioid use disorder, researchers found a signal that semaglutide might lower the risk of opioid overdoses by as much as two-thirds. “It’s a […]

The abrupt and immediate departure of Sima Sistani as CEO of Weight Watchers prompts us to ask: Is the diet industry dead? Weight Watchers grew from its origins in the early 1960s to become the iconic brand that dominated this field. For decades now, the popular impulse to reject diet culture has been growing. In […]

This year, the Lasker-DeBakey Clinical Medical Research Award recognizes research on GLP-1 receptor biology that is revolutionizing obesity medicine. This is a revolution that is sending shockwaves through all of healthcare and indeed through society. Revolutions are uncomfortable and many people look at progress such as this with regretful nostalgia or outright fear. So we […]

The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]

In every way we look at this study, it is a remarkable milestone. With a randomized, controlled trial, Claudia Fox and colleagues have shown that a GLP-1, liraglutide, is effective for obesity in children as young as six years of age. In this year-long study, children who received liraglutide for obesity reduced their body mass […]

Consumer spending is by far the biggest driver of U.S. economic growth. So you can be sure that businesses are paying close attention to the disruption in longstanding consumer behavior patterns that GLP-1 medicines are bringing. People are buying new clothes, better food, spending less on weight watching, and more on health. Make no mistake. […]

Think about it. Profound change is coming to healthcare and health systems because of the imperative for obesity care at scale. Right now, we are seeing only a faint glimmer of the changes that lie ahead. That’s because the biggest struggles with this change are very basic. Lilly and Novo Nordisk are straining to produce […]